Skip to main content

Table 3 Quality of life of included participants

From: Sustained virologic response improved the long-term health-related quality of life in patients with chronic hepatitis C: a prospective national study in China

 

Baseline

(n = 456)

1st year

(n = 335)

2nd year

(n = 331)

3nd year

(n = 302)

4th year

(n = 253)

5th year

(n = 209)

Moderate

Severe

Moderate

Severe

Moderate

Severe

Moderate

Severe

Moderate

Severe

Moderate

Severe

EQ-5D

            

 MO, n (%)

31(6.8)

2(0.4)

19(5.7)

0(0)

17(5.1)

1(0.3)

17(5.6)

1(0.3)

17(6.7)

0(0)

16(7.7)

0(0)

 SC, n (%)

5(1.1)

1(0.2)

4(1.2)

0(0)

4(1.2)

0(0)

3(1.0)

0(0)

1(0.4)

0(0)

1(0.5)

0(0)

 UA, n (%)

19(4.2)

3(0.6)

18(5.4)

0(0)

14(4.2)

1(0.3)

11(3.6)

0(0)

13(5.1)

0(0)

11(5.3)

0(0)

 PD, n (%)

96(21.1)

5(1.1)

57(17.0)

3(0.9)

56(16.9)

3(0.9)

56(18.5)

1(0.3)

36(14.2)

1(0.4)

27(12.9)

1(0.5)

 AD, n (%)

96(21.1)

2(0.4)

42(12.5)

1(0.3)

38(11.5)

3(0.9)

31(10.3)

1(0.3)

23(9.1)

0(0)

18(8.6)

1(0.5)

EQ-5D index, mean ± SD

0.916 ± 0.208

0.938 ± 0.177

0.936 ± 0.199

0.943 ± 0.153

0.956 ± 0.125

0.949 ± 0.159

EQ-5D VAS, mean ± SD

80.6 ± 13.0

82.1 ± 12.2

83.4 ± 12.7

85.9 ± 12.6

85.8 ± 13.1

86.9 ± 12.1

  1. a Patients reported some problem (moderate or severe) in individual domain. MO, mobility difficulties; SC, self-care difficulties; UA, usual activities difficulties; PD, pain/discomfort; AD, anxiety/depression